RSNA Launches COVID-19 Imaging Data Repository
Open database will assist with disease detection and differentiation.
In answer to a global call from the healthcare community and in an effort to expand the body of knowledge around the COVID-19 pandemic, the Radiological Society of North America (RSNA) is launching the COVID-19 Imaging Data Repository.
The open database will collect COVID-19 images and data from institutions, practices, and professional societies worldwide, building a comprehensive source for research and education efforts pertaining to the virus. All images and data will collected securely and in a way that maintains privacy and ethical principles.
“RSNA is committed to accelerating collaborative research and education on the uses of medical imaging to address diagnosis and imaging-based treatment of COVID-19,” said Curtis P. Langlotz, M.D., Ph.D., RSNA Board Liaison for Information Technology and Annual Meeting, in an announcement. “Because RSNA is a leader in connecting radiologists around the world, we have received a wave of requests from organizations interested in sharing imaging data, as well as from individuals and organizations seeking access to such data for research and education.”
Providers, practices, and organizations interested in submitting COVID-19 images and related information to the repository can respond to an RSNA survey. Expression of interest and responses are requested by April 15, 2020.
Similar to RSNA’s other data-sharing efforts with images, research, and technologic innovation, this repository will be grounded in collaboration with other imaging organizations, particularly the European Imaging COVID-19 AI Initiative that is supported by the European Society of Medical Imaging Informatics.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
